GUILLERMO GARCIA-MANERO to Activin Receptors, Type II
This is a "connection" page, showing publications GUILLERMO GARCIA-MANERO has written about Activin Receptors, Type II.
Connection Strength
1.359
-
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial. Blood. 2022 01 27; 139(4):624-629.
Score: 0.842
-
Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with?ring sideroblasts. Blood. 2022 11 17; 140(20):2170-2174.
Score: 0.223
-
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N Engl J Med. 2020 01 09; 382(2):140-151.
Score: 0.183
-
Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts. Leukemia. 2023 11; 37(11):2314-2318.
Score: 0.059
-
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leukemia. 2022 05; 36(5):1432-1435.
Score: 0.053